IINN

BEARISH

$0.42 Live

Inspira Technologies Oxy B.H.N. Ltd. · NASDAQ

Target $5.0 (+1076.7%)

$0.34 52W Range $1.65

IINN Inspira Technologies Oxy B.H.N. Ltd. - Fundamental Analysis

BEARISH

Console Chart News

IINN Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$0.42

Analyst Target

$5.0

+1076.7% Upside

52W High

$1.65

52W Low

$0.34

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026

Market cap

$18.52M

P/E

N/A

ROE

-397.9%

Profit margin

N/A

Debt/Equity

0.21

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

95%

IINN exhibits severe fundamental distress, characterized by a Piotroski F-Score of 4/9, which barely maintains a 'stable' rating despite catastrophic operational metrics. The company's operating margin of -4713.84% and a Price-to-Sales ratio of 64.07 indicate a massive disconnect between market valuation and actual revenue generation. With a 5-year price decline of 91% and a technical trend score of 0/100, the stock is in a persistent freefall. The absence of an Altman Z-Score and Graham Number further underscores the lack of positive earnings or stable equity to support a traditional valuation.

Key Strengths

Low Debt/Equity ratio (0.21)

Current Ratio of 1.56 suggests adequate short-term liquidity

Quick Ratio of 1.12 indicates ability to cover immediate liabilities

Low overall leverage compared to healthcare sector average

Speculative upside if the single analyst's $5.00 target is realized

Key Risks

Extreme operational inefficiency (Operating Margin: -4713.84%)

Negligible Gross Margin (0.69%) suggesting no pricing power or high COGS

Severe valuation bubble relative to sales (P/S: 64.07)

Consistent long-term value destruction (-91% 5Y change)

Negative ROE (-397.89%) indicating rapid erosion of shareholder equity

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Catastrophic operating margins, Extreme P/S ratio, Severe technical downtrend, Negative equity returns

Confidence

90%

Value

5/100

Ref P/E, PEG, Graham Number

Positives

No standout positives identified.

Watchpoints

P/S of 64.07 is unsustainable
P/B of 6.54 is high for a non-profitable entity
No Graham Number available due to negative earnings

Future

15/100

Ref Growth rates

Positives

Single analyst target price of $5.00

Watchpoints

Negative Forward P/E
Lack of reported revenue growth
Poor profitability trajectory

Past

10/100

Ref Historical trends

Positives

No standout positives identified.

Watchpoints

5Y Change: -91%
6M Change: -62.4%
Consistent downward price momentum

Health

40/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Low Debt/Equity
Current Ratio > 1.0

Watchpoints

Piotroski F-Score 4/9 is mediocre
Altman Z-Score unavailable
Extreme ROE/ROA losses

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend yield
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$0.42

Analyst Target

$5.0

Upside/Downside

+1076.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for IINN and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
IINN Inspira Technologies Oxy B.H.N. Ltd. Primary	-91.0%	-65.5%	-31.4%	-62.4%	-26.0%	-11.8%
CUE Cue Biopharma, Inc. Peer	-98.5%	-94.2%	-69.9%	-75.0%	-37.5%	-18.2%
HBIO Harvard Bioscience, Inc. Peer	-93.5%	-91.5%	+10.5%	+2.6%	-15.5%	-17.1%
AIDX 20/20 Biolabs, Inc. Peer	-92.0%	-92.0%	-92.0%	-92.0%	-32.8%	+1.6%
GNTA Genenta Science S.p.A. Peer	-93.8%	-88.7%	-82.4%	-79.4%	-21.2%	-4.4%

IIN

Inspira Technologies Oxy B.H.N. Ltd.

Primary

-91.0%

-65.5%

-31.4%

-62.4%

-26.0%

-11.8%

CUE

Cue Biopharma, Inc.

Peer

-98.5%

-94.2%

-69.9%

-75.0%

-37.5%

-18.2%

HBI

Harvard Bioscience, Inc.

Peer

-93.5%

-91.5%

+10.5%

+2.6%

-15.5%

-17.1%

AID

20/20 Biolabs, Inc.

Peer

-92.0%

-32.8%

+1.6%

GNT

Genenta Science S.p.A.

Peer

-93.8%

-88.7%

-82.4%

-79.4%

-21.2%

-4.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-0.61

N/A

6.54

64.07

54.8

-1.18

$18.52M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -4713.84%

Gross Margin 0.69%

ROE -397.89%

ROA -126.98%

Growth

Revenue and earnings growth rates

Revenue Growth N/A

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.21

Low debt

Current Ratio

1.56

Good

Quick Ratio

1.12

Good

Cash/Share

$0.07

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets

$0.0B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

1.30x

Healthcare Sector Comparison

Comparing IINN against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)

Return on Equity (ROE)

-397.89%

This Stock

-46.09%

Sector Avg

+763.4% (Excellent)

Debt to Equity

0.21

This Stock

4.1

Sector Avg

-95.0% (Less Debt)

Current Ratio

1.56

This Stock

3.58

Sector Avg

-56.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
IINN Inspira Technologies Oxy...	BEARISH	$18.52M	-	-397.9%	-%	$0.42
CUE Cue Biopharma, Inc.	NEUTRAL	$18.38M	-	-121.1%	-96.9%	$0.19	Compare
HBIO Harvard Bioscience, Inc.	BEARISH	$19.27M	-	-147.1%	-65.5%	$4.31	Compare
AIDX 20/20 Biolabs, Inc.	BEARISH	$19.95M	-	-503.1%	-182.8%	$1.91	Compare
GNTA Genenta Science S.p.A.	BEARISH	$16.02M	-	-38.0%	-%	$0.68	Compare

IINN Inspira...

BEARISH

Mkt Cap

$19M

P/E

ROE

-397.9%

Price

$0.42

CUE Cue Biopharma, Inc.

Compare with IINN

Compare with IINN

AIDX 20/20 Biolabs, Inc.

Compare with IINN

GNTA Genenta Science S.p.A.

Compare with IINN

Past News Coverage

Recent headlines mentioning IINN from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

IINN

IINN Inspira Technologies Oxy B.H.N. Ltd. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Healthcare Sector Comparison

Similar Companies

Past News Coverage

Wait — Don't Miss Out!